Сhanges in the composition of gut microbiota in patients with chronic hepatitis С, non-alcoholic fatty liver disease at different stages of liver disease: a review

INTRODUCTION. The human gut microbiota is a set of microorganisms that are in symbiosis with the host organism. The predominance of bacteria of Bacteroidetes, Firmicutes, Actinobacteria types is a characteristic feature of human gut microbiota. However, the composition of the gut microbiota is subject to change under the influence of a number of factors. The influence of the gut-liver axis on the pathogenesis of many chronic liver diseases of various etiologies, both infectious and metabolic, has been proven. At the same time, in the analyzed literature, the data on the relationship between the nature of GM changes and the stage of liver damage are quite controversial.

OBJECTIVE. Updating and systematization of ideas about the nature of changes in the composition of intestinal microbiota in chronic hepatitis C (CHC) and non-alcoholic fatty liver disease (NAFLD) at different stages of the disease.

MATERIALS AND METHODS. We analyzed the scientific literature on GM changes in chronic liver diseases with regard to their etiology and disease stage, in particular in chronic viral hepatitis C and NAFLD. The search was conducted in PubMed, Google Scholar, and eLIBRARY databases for 2000-2023 using the following keywords: gut microbiota; microbiota in hepatitis C; microbiota in NAFLD; microbiota in liver fibrosis; liver fibrosis progression. Sixty scientific articles were analyzed and 42 sources were selected, of which more than 60% were published within the last five years.

RESULTS. This review presents the results of original studies describing the main taxonomic differences between the microbiomes of healthy individuals and patients with CHC complicated by the formation of liver cirrhosis and hepatocellular carcinoma (HCC). Thus, patients with viral cirrhosis showed impoverishment of intestinal commensals Lachnospiraceae and Ruminococcaceae and significant enrichment of Streptococcaceae, Lactobacillaceae and Enterobacteriaceae. In patients with non-alcoholic steatohepatitis (NASH) and F>II, enrichment of GM Phylum Bacteroides and Proteobacteria, Families Lachnospiraceae and Enterobacteriaceae, Genera Blautia and Escherichia, with a concomitant decrease of Prevotella was detected.

DISCUSSION. The analysis of GM taxonomic units in the previously described studies did not reveal significant differences depending on the etiology of the underlying disease. However, a decrease in the representative of the phylum Firmicutes - Ruminococcaceae was observed in CHC in contrast to NAFLD. A more distinct relationship can be observed in the changes of intestinal microbiota in F(III-IV) irrespective of etiology. Thus, in advanced liver fibrosis and cirrhosis of both CHC and NAFLD etiologies, enrichment of GM has been described due to an increase in phylum Proteobacteria, in particular the genus Escherichia and phylum Firmicutes (Blautia, Veillonellaceae). In the studies analyzed, at F(III-IV), an enrichment of the microbiota is observed due to an increase in the phylum Bacteroidetes. Regarding the genus Prevotella, contradictory results were found. In addition, there are ambiguous data regarding the genera Lactobacillus, Ruminococcaceae and Bifidobacteria.

CONCLUSION. Based on the results of the literature review, we obtained contradictory data on GM composition in patients with CHC and NAFLD. This may be due to the size of samples, heterogeneity of initial data during the selection of patients in the study. The relationship between the composition of microbiota and persistent inflammatory process, expressed liver fibrosis is observed. GM reflects not only functional disorders in chronic liver diseases of various etiologies, but can also serve as a diagnostic indicator of their progression.

marine medicine, gut microbiota, microbiome, chronic hepatitis C, non-alcoholic fatty liver disease, NAFLD, liver fibrosis, cirrhosis of the liver, progression of liver fibrosis, microbiota in hepatitis C, microbiota in NAFLD, microbiota in liver fibrosis

1. Milosevic I., Vujovic A., Barac A. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature. Int. J. Mol. Sci., 2019, Vol. 20, pp. 395. doi: 10.3390/ijms20020395.

2. Bajaj J.S., Heuman D. M., Hylemon P. B., et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J. Hepatol., 2014, Vol. 60, N 5. pp. 940–947. doi: 10.1016/j.jhep.2013.12.019.

3. Венцловайте Н.Д., Горячева Л.Г., Гончар Н.В., Грешнякова В.А., Ефремова Н.А. Патогенетическая связь между состоянием микробиоты кишечника и заболеваниями печени // Инфекционные болезни: новости, мнения, обучение. 2022. Т. 11, № 2. С. 97–105. doi: 10.33029/2305-3496-2022-11-2-97-105. [Venclovayte N.D., Goryacheva L.G., Gonchar N.V., Greshnyakova V.A., Efremova N.A. Pathogenetic relationship between the state of the intestinal microbiota and liver diseases. Infectious diseases: news, opinions, training, 2022, Vol. 11, No. 2, pp. 97–105 (In Russ.)].

4. Tap J., Mondot S., Levenez F., et al. Towards the human intestinal microbiota phylogenetic core. Environ. Microbiol. 2009, 11, pp. 2574–2584. doi: 10.1111/j.1462-2920.2009.01982.x.

5. Arumugam M., et al. Enterotypes of the human gut microbiome. Nature. 2011; Vol.7346, No. 473, pp. 174-180. doi: 10.1038/nature09944.

6. Tyakht A., Kostryukova E., Popenko A., et al. Human gut microbiota community structures in urban and rural populations in Russia. Nat Commun, 2013, No. 4, pp. 2469. doi: 10.1038/ncomms3469.

7. Saeed N.K., Al-Beltagi M., Bediwy A.S. Gut microbiota in various childhood disorders: Implication and indications. World J Gastroenterol, 2022, Vol. 28, No. 18, 1875–1901. doi: 10.3748/wjg.v28.i18.1875.

8. Yatsunenko T., Rey F.E., Manary M.J. Human gut microbiome viewed across age and geography. Nature. 2012, Vol. 7402, No. 486, 222-227. doi: 10.1038/nature11053.

9. Albillos A., de Gottardi A., Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. J Hepatol. 2020, Vol. 72, No. 3, 558–577. doi: 10.1016/j.jhep.2019.10.003.

10. Tilg H., Adolph T.E., Trauner M. Gut-liver axis: Pathophysiological concepts and clinical implications. Cell Metab. 2022, Vol. 34, No. 11, pp. 1700–1718. doi: 10.1016/j.cmet.2022.09.017.

11. Yiu J.H., Dorweiler B., Woo C.W. Interaction between gut microbiota and toll-like receptor: From immunity to metabolism. J. Mol. Med. 2017, No. 95, pp. 13–20. Munteanu D., Negru A., Radulescu M. Evaluation of bacterial translocation in patients with chronic HCV infection. Rom. J. Intern. Med., 2014, Vol. 52, pp. 91–96. doi: 10.1007/s00109-016-1474-4.

12. Suk K.T., Kim D.J. Gut microbiota: Novel therapeutic target for nonalcoholic fatty liver disease. Expert Rev. Gastroenterol. Hepatol. 2019, No. 13, pp. 193–204. doi: 10.1080/17474124.2019.1569513.

13. Ebrahimzadeh L. H., Ghotaslou R., Samadi Kafil H. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies. Eur J Clin Microbiol Infect Dis. 2020, Vol. 39, No. 4, 613–627. doi: 10.1007/s10096-019-03746-1.

14. Yang R., Xu Y., Dai Z.The Immunologic Role of Gut Microbiota in Patients with Chronic HBV Infection. J. Immunol. Res., 2018, Vol. 2018, pp. 2361963. doi: 10.1155/2018/2361963.

15. Aly A.M., Adel A., El-Gendy A.O. Gut microbiome alterations in patients with stage 4 hepatitis C. Gut Pathog., 2016, No. 8, pp. 42. doi: 10.1186/s13099-016-0124-2.

16. Heidrich B., Vital M., Plumeier I., et al. Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls. Liver Int. 2018, Vol. 38, pp. 50–58.

17. Inoue T., Nakayama J., Moriya K., Kawaratani H. et al. Gut Dysbiosis associated with hepatitis C virus infection. Clin. Infect. Dis. 2018; No. 67, pp. 869–877. doi: 10.1093/cid/ciy205. doi: 10.1111/liv.13485.

18. Ullah N., Kakakhel M.A., Khan I. et al. Structural and compositional segregation of the gut microbiota in HCV and liver cirrhotic patients: A clinical pilot study. Microb Pathog., 2022, No. 171, pp. 105739. doi: 10.1016/j.micpath.2022.105739.

19. Zhiming L., Ming N., Haiyang Yu. Gut Microbiota and Liver Fibrosis: One Potential Biomarker for Predict Liver Fibrosis. Bio Med Research International, vol. 2020. doi: 10.1155/2020/3905130.

20. Boursier J., Mueller O., Barret M. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology., 2016, Vol. 63, No. 3, pp. 764–775. doi: 10.1002/hep.28356.

21. Shen F., Zheng R.D., Sun X.Q. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int., 2017, Vol. 16, No. 4, pp. 375–381. doi: 10.1016/S1499-3872(17)60019-5.

22. Loomba R., Seguritan V., Li W. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. Cell Metab., 2017, Vol. 25, No. 5, 1054–1062. e5. doi: 10.1016/j.cmet.2017.04.001.

23. Sharpton S.R., Podlaha O., Chuang J.C. Changes in the gut microbiome associated with liver stiffness improvement in nonalcoholic steatohepatitis. Therap Adv Gastroenterol., 2022, No. 15, 17562848221098243. doi: 10.1177/17562848221098243.

24. Schwimmer J.B., Johnson J.S., Angeles J.E. et al. Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2019, Vol. 157, No. 4, 1109–1122. doi: 10.1053/j.gastro.2019.06.028.

25. Marascio N, De Caro C, Quirino A. The Role of the Microbiota Gut-Liver Axis during HCV Chronic Infection: A Schematic Overview. J Clin Med., 2022, Vol. 19, No. 11, pp. 5936. doi: 10.3390/jcm11195936.

26. Preveden T., Scarpellini E., Milic N., Luzza F., Abenavoli L. Gut microbiota changes and chronic hepatitis C virus infection. Expert Rev. Gastroenterol. Hepatol., 2017, No. 11, pp. 813–819. doi: 10.1080/17474124.2017.1343663.

27. El-Mowafy M, Elgaml A, El-Mesery M. Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection. Biology (Basel)., 2021, Vol. 10, No. 1, pp. 55. doi: 10.3390/biology10010055.

28. Lim T.R., Hazlehurst J.M., Oprescu A.I., Armstrong M.J., Abdullah S.F., Davies N.P., Flintham R., Balfe P., Mutimer D.J., McKeating J.A., Tomlinson J.W. Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure. Clin Endocrinol (Oxf)., 2019, Vol. 90, No. 3, 440–448. doi: 10.1111/cen.13924.

29. Wang C.C., Cheng P.N., Kao J.H. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther., 2020, Vol. 51, No. 2, pp. 216–230. doi: 10.1111/apt.15575

30. Adinolfi LE, Rinaldi L, Guerrera B. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations. Int J Mol Sci., 2016, Vol. 17, No. 6, pp. 803. doi: 10.3390/ijms17060803.

31. Chen D., Le T.H., Shahidipour H. The Role of Gut-Derived Microbial Antigens on Liver Fibrosis Initiation and Progression. Cells, 2019, No. 8, pp. 1324. doi: 10.3390/cells8111324.

32. Vajro P., Paolella G., Fasano A. Microbiota and Gut–Liver Axis: Their Influences on Obesity and Obesity-Related Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2013, Vol. 56, No. 5, pp. 461–468. doi: 10.1097/MPG.0b013e318284abb5.

33. Zhu L., Baker S.S., Gill C., Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology, 2013, Vol. 57, No. 2, pp. 601-609. doi: 10.1002/hep.26093.

34. Michail S., Lin M., Frey M.R. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol., 2015, Vol. 91, No. 2, pp. 1–9. doi: 10.1093/femsec/fiu002.

35. Cope K., Risby T., Diehl A.M. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology, 2000, Vol. 119, No. 5, 1340–1347. doi: 10.1053/gast.2000.19267.

36. Raman M., Ahmed I., Gillevet P.M. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol., 2013, Vol. 11, No. 7, pp. 868-875.e1-3. doi: 10.1016/j.cgh.2013.02.015.

37. Del Chierico F., Nobili V., Vernocchi P. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology., 2017, Vol. 65, No. 2, pp. 451–464. doi: 10.1002/hep.28572.

38. Yuan J., Chen C., Cui J., et al. Fatty Liver Disease Caused by High-Alcohol-Producing Klebsiella pneumoniae. Cell Metab., 2019, Vol. 30, No. 4, pp. 675–688.e7. doi: 10.1016/j.cmet.2019.08.018.

39. Zhu L., Baker R.D., Baker S.S. Gut microbiome and nonalcoholic fatty liver diseases. Pediatr Res., 2015, Vol. 77, No. 1–2, pp. 245–251. doi: 10.1038/pr.2014.157.

40. Iogna Prat L., Tsochatzis E.A. Pediatric NAFLD: lessons from the gut. Hepatobiliary Surg Nutr., 2020, Vol. 9, No. 4, pp. 534–536. doi: 10.21037/hbsn.2020.01.06.

41. Bastian W.P., Hasan I., Lesmana C.R.A. Gut Microbiota Profiles in Nonalcoholic Fatty Liver Disease and Its Possible Impact on Disease Progression Evaluated with Transient Elastography: Lesson Learnt from 60 Cases. Case Rep Gastroenterol. 2019, Vol. 13, No. 1, 125–133. doi: 10.1159/000498946.